SPORE in Prostate Cancer

描述（由申请人提供）：自1995年成立以来，密歇根大学综合癌症中心（UMCCC）前列腺癌SPORE一直致力于利用密歇根大学社区的大量智力和物质资源来降低前列腺癌的发病率和死亡率。SPORE支持一个基础和临床研究人员的互动小组进行转化研究计划，该计划在开发前列腺癌诊断，预防和治疗的新干预措施方面取得了重大发现。今年，我们的综合研究团队共同努力，利用SPORE资源，赢得了第一届年度AACR团队科学奖，以表彰他们发现TMPRSS：ETS家族基因融合在前列腺癌肿瘤发生中的重要性，这证明了SPORE的转化使命的成功。该奖项由美国癌症研究协会（AACR）设立，旨在表彰和促进跨学科团队对理解癌症和/或将研究发现转化为临床癌症应用的日益重要性。该竞争性更新申请包括四个多学科研究项目：项目1：基于复发性基因融合的前列腺癌分子亚型。项目2：小分子方法重新激活p53活性作为治疗晚期人类前列腺癌的新治疗策略。项目3：确定前列腺癌患者兄弟的遗传风险因素。项目4：全身性抑制单核细胞趋化蛋白-1（MCP-1; CCL 2）治疗前列腺癌。这些项目得到了正在进行的成功的职业发展和研究发展计划的补充。这些项目和计划得到了资金和空间以及三个核心的强有力的持续机构承诺的支持：管理核心，生物统计核心和组织核心。这个前列腺孢子计划继续重视对其转化研究计划的严格科学审查，基础和临床研究人员的配对，借鉴前列腺癌领域以外科学家的专业知识，并利用灵活性为有前途的新研究方法提供资金。我们的多学科研究小组的相互作用显然使密歇根大学综合癌症中心的前列腺孢子计划大于其各个部分的总和。

DESCRIPTION (provided by applicant): Since its inception in 1995, the University of Michigan Comprehensive Cancer Center (UMCCC) Prostate Cancer SPORE has endeavored to tap the vast intellectual and physical resources of the University of Michigan community to decrease the morbidity and mortality of prostate cancer. The SPORE supports an interactive group of basic and clinical investigators in a translational research program that has made major discoveries in developing new interventions in the diagnosis, prevention, and treatment of prostate cancer. The success of the translational mission of the SPORE was exemplified this year by our integrated team of investigators working together and utilizing SPORE resources to win the 1st annual AACR Team Science Award for the discovery of the importance of the TMPRSS:ETS family gene fusions in prostate cancer tumorigenesis. This Award was established by the American Association for Cancer Research (AACR) to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. This competing renewal application consists of four multidisciplinary research projects: Project 1: Molecular Sub-typing of Prostate Cancer Based on Recurrent Gene Fusions. Project 2: Small-molecule approach to reactivate p53 activity as a new therapeutic strategy for the treatment of advanced human prostate cancer. Project 3: Defining Genetic Risk Factors for Brothers of Men with Prostate Cancer. Project 4: Systemic inhibition of monocyte chemoattractant protein -1 (MCP-1; CCL2) for the treatment of prostate cancer. These projects are complemented by ongoing successful Career Development and Research Development Programs. The projects and programs are supported by a strong ongoing institutional commitment of money and space as well as three cores: Administration Core, Biostatistics Core, and the Tissue Core. This Prostate SPORE program continues to place premiums on rigorous scientific reviewing of its translational research programs, pairing of basic and clinical investigators, drawing on the expertise of scientists outside the field of prostate cancer, and utilizing flexibility to fund promising new research approaches. The interaction of our multidisciplinary group of investigators clearly makes the Prostate SPORE program at the University of Michigan Comprehensive Cancer Center greater than the sum of its individual parts.